Approximately 100M Americans report at least one sunburn every year. In 2024 consumers spent about $2.35B on “after-sun” lotions and gels, and $1.44B on medicated OTC or prescription sunburn treatments (topical corticosteroids, lidocaine/NSAIDs, moisturizers) globally, with the USA alone accounting for approximately $1B. If we charge $50/bottle (the low end of elite cosmetics products), users buy only 5 bottles per year (a very conservative estimate), and we capture 10% of those 100M sunburned Americans, it is trivial to envision a $2.5B revenue opportunity for just the first product aimed at the general population.

One specific vertical in and of itself is the leisure cruise market, identified in our original customer discovery efforts. 19M Americans go on cruises every year, and reports show that up to 25% get sunburned. Focusing solely on this market segment of 5M people, capturing 10% of that market (500k people) purchasing 5 bottles per cruise leads us to a $125M revenue opportunity as part of cruises alone. A first-in-class sunburn-blocking biologic that addresses redness, not just treats it, could capture even 5% of that TAM within five years, a penetration rate in line with recent dermatology roll-outs.